

September 1, 2021
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**SymBio enters into a collaborative research agreement with the
National Cancer Centre Singapore on Epstein-Barr virus positive lymphoma**

TOKYO, Japan, September 1, 2021 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that it has entered a collaborative research agreement with the National Cancer Centre Singapore (NCCS) to explore anti-tumor activity and the mechanism of brincidofovir (BCV) IV in Epstein-Barr virus (EBV)¹ positive lymphoma.

"This study aims to clarify the mechanism of action of BCV against EBV positive lymphoma. Based on the findings, we hope to conduct clinical trials for patients with malignant lymphoma who may benefit from treatment using BCV." said Dr. Jason Yongsheng Chan, Principal Investigator of the study, Consultant in the Division of Medical Oncology, NCCS and Clinical Assistant Professor at Duke-NUS Medical School.

Statement from Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio: "BCV has a wide range of antiviral effects against dsDNA viruses and is expected to be effective against EBV-related diseases. EB viruses found in tumors and their viral proteins have been shown to be associated with disease by acting on intracellular signals to promote cellular tumorigenesis. This study will elucidate the mechanism of action of BCV against EB virus-positive lymphoma, toward the development of new therapies."

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

(Note 1) Epstein-Barr virus (EBV)

The EBV is one of the human herpesvirus types and firstly investigated in the Burkitt lymphoma in child, prevalent mainly in Africa, in 1964 as the oncogenic virus. Infection with EBV in childhood is usually asymptomatic or mild disease. When infection with EBV occurs during adolescence, it causes infectious mononucleosis accompanied by transient fever, sore throat or lymphadenopathy. The causal relationship of EBV with some malignant lymphoma, nasopharyngeal cancer and so on has been clarified.

About Anti-viral Drug Brincidofovir

Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved and marketed in the United States and the European Union, but unapproved in Japan. As BCV exhibits not only higher anti-viral activity, but also a superior safety profile in comparison with CDV, BCV is expected to be an effective treatment against a wide spectrum of dsDNA viruses such as herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV) and BK virus, papillomavirus. Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent that can reduce the risk of nephrotoxicity, which is a serious side effect of CDV.

SymBio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants SymBio exclusive worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of orthopox infections (which includes smallpox and monkeypox).

About the National Cancer Centre Singapore

The National Cancer Centre Singapore (NCCS) provides a holistic and multi-disciplinary approach to cancer treatment and patient care. NCCS sees close to 65 per cent of Singapore's public sector oncology cases, and they are benefiting from the sub-specialization of NCCS' clinical oncologists.

To deliver among the best in cancer treatment and care, NCCS' clinicians work closely with scientists who conduct robust, cutting-edge clinical and translational research programs which are internationally recognized. NCCS strives to be a global leading cancer centre, and shares its expertise and knowledge by offering training to local and overseas medical professionals.

For more information, please visit: www.nccs.com.sg

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. In June 2021, the U. S. Food and Drug Administration granted approval of TEMBEXA® for the treatment of smallpox as a medical countermeasure. Chimerix has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and blinded independent central review is expected later in 2021. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia. For further information, please visit the Chimerix website, www.chimerix.com.

About Symbio Pharmaceuticals Limited

Symbio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called Symbio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.